BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34997982)

  • 1. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
    Wang B; Chao S; Guo B
    J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
    Wu M; Sun Y; Wu J; Liu G
    Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
    Zhang L; Zhang X; Fan S; Zhang Z
    Medicine (Baltimore); 2019 Nov; 98(44):e17803. PubMed ID: 31689861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    Topno R; Singh I; Kumar M; Agarwal P
    BMC Cancer; 2021 Mar; 21(1):220. PubMed ID: 33663405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Critical Genes Involved in Metastasis and Prognosis of High-Grade Serous Ovarian Cancer by Gene Expression Profile Data.
    Wang R; Du X; Zhi Y
    J Comput Biol; 2020 Jul; 27(7):1104-1114. PubMed ID: 31725318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
    Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
    BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
    Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.
    Sun Q; Zhao H; Zhang C; Hu T; Wu J; Lin X; Luo D; Wang C; Meng L; Xi L; Li K; Hu J; Ma D; Zhu T
    Oncotarget; 2017 Jun; 8(26):42983-42996. PubMed ID: 28562334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four genes relevant to pathological grade and prognosis in ovarian cancer.
    Pan X; Chen Y; Gao S
    Cancer Biomark; 2020; 29(2):169-178. PubMed ID: 32444534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
    Niemira M; Erol A; Bielska A; Zeller A; Skwarska A; Chwialkowska K; Kuzmicki M; Szamatowicz J; Reszec J; Knapp P; Moniuszko M; Kretowski A
    Sci Rep; 2023 Nov; 13(1):19287. PubMed ID: 37935712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.
    Si M; Zhang J; Cao J; Xie Z; Shu S; Zhu Y; Lang J
    Onco Targets Ther; 2019; 12():10057-10075. PubMed ID: 31819501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
    Kim SI; Hwangbo S; Dan K; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
    Mol Cell Proteomics; 2023 Mar; 22(3):100502. PubMed ID: 36669591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.